Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK and Novartis pledge funds for diseases that primarily affect the poor

Rise and shine, everyone, another busy day is coming up. We can tell because Mrs. Pharmalot and the official mascot are long gone for their morning build-up, another food delivery is imminent, and our to-do list has already grown. It calls for, as you can imagine, a cup or three of stimulation. Our pick today is pumpkin spice, which was hiding at the back of our pantry. In the meantime, here is the latest list of interesting articles to help you on your journey today. We hope all goes well and you conquer the world. But while you do, remember to stay in touch. We appreciate juicy advice…

A new proposal that senators say would fix the price of insulin would actually allow drugmakers to lock in their current profits from the drug for the foreseeable future, explains STAT. The bill, introduced Wednesday by the senses. Jeanne Shaheen (DN.H.) and Susan Collins (R-Maine), offer a convoluted overhaul of the pricing of insulin products and what patients pay for them. The proposal could help a minority of patients who use insulin, and Senate leadership hopes to speed up the vote this summer. But the fix would likely spread the costs across all Medicare patients, insurers and the federal government, without actually changing how much drugmakers earn on the drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Norman D. Briggs